Production (Stage)
Design Therapeutics, Inc.
DSGN
$3.84
-$0.07-1.79%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 26.49% | 2.37% | |||
| Gross Profit | -26.49% | -2.37% | |||
| SG&A Expenses | 11.11% | 3.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 22.31% | 2.76% | |||
| Operating Income | -22.31% | -2.76% | |||
| Income Before Tax | -29.77% | -4.69% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -29.77% | -4.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -29.77% | -4.69% | |||
| EBIT | -22.31% | -2.76% | |||
| EBITDA | -22.45% | -2.81% | |||
| EPS Basic | -29.61% | -4.56% | |||
| Normalized Basic EPS | -29.63% | -4.59% | |||
| EPS Diluted | -29.61% | -4.56% | |||
| Normalized Diluted EPS | -29.63% | -4.59% | |||
| Average Basic Shares Outstanding | 0.13% | 0.11% | |||
| Average Diluted Shares Outstanding | 0.13% | 0.11% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||